When PSMA-targeted therapy ceases to be effective, patients often experience a general shift: what once seemed like a stable treatment plan suddenly becomes uncertain. The disease continues to develop, and conventional options dry up, at which point people start seeking treatment that they cannot access at home. Germany has become one of the main targets for Actinium-225, a treatment used when PSMA-based therapy loses effectiveness.
This article explains what Actinium‑225 therapy is, why Germany plays such a central role, and how patients make practical decisions from choosing a clinic to understanding a doctor’s experience.
What Actinium‑225 Alpha Therapy Actually Is and Why It Can Work After PSMA Failure
Actinium-225 PSMA therapy targets the same PSMA marker as Lu‑177, but it works differently. Lu‑177 spreads its radiation wider, so when the cancer becomes uneven, some spots get missed. Actinium‑225 hits over a very short distance but much harder, which is why it can still affect cells that no longer respond to Lu‑177.
German university hospitals began using alpha‑therapy earlier than other countries and have built significant experience over the years. That’s why many international patients end up there. In German centers, around 40–60% of patients show a response even after PSMA therapy stops working.
The Airomedical platform helps with the practical part — checking which hospitals actually take international patients and which doctors truly work with radioligand therapy, so people don’t waste time sending documents to the wrong place.
What Treatment in Germany Looks Like: Step‑by‑Step
Actinium‑225 therapy in Germany follows a simple process. After the remote review, patients plan a short visit. The first day is spent updating blood tests and repeating imaging, if needed.
The injection itself is brief. Actinium‑225 is given intravenously, followed by a few hours of observation. Because alpha‑emitters have an extremely short tissue range, radiation precautions are minimal. Most patients feel well enough to return to their hotel the same day. Many stay in Germany for one or two additional days for early monitoring.
After returning home, monitoring continues remotely. Side effects may occur gradually. Most commonly, dry mouth, mild fatigue, or temporary changes in blood. The response to treatment is evaluated later. The new PSMA PET/CT is performed 8-12 weeks after the first cycle to decide if another cycle is suitable. Most patients receive two or three cycles if the therapy is well-tolerated and beneficial.
Who Is a Good Candidate for Actinium‑225 Therapy
Actinium‑225 is generally considered for patients with PSMA‑expressing metastatic disease that has progressed despite prior PSMA‑targeted treatments such as Lu‑177. The strongest candidates are those with clearly PSMA‑positive lesions on recent imaging and with bone marrow, kidney, and liver function sufficient to tolerate radioligand therapy. German teams also look at the overall pace of the disease — patients with steady, not explosive, progression tend to benefit most.
Eligibility is always personalized. Some patients with mixed PSMA may still meet the requirements if most lesions remain positive for PSMA. Others may need an updated examination before a final decision is made.
Choosing the Right German Center for Actinium‑225 Therapy
German centers offering Actinium‑225 therapy fall into two groups: large university hospitals and specialized nuclear medicine clinics. University hospitals offer broader diagnostic services and multidisciplinary teams. In contrast, private clinics often offer shorter waiting times and more flexible scheduling. For Actinium‑225, both can be appropriate — what matters most is the experience of the nuclear medicine team, not the size or branding of the hospital.
Patients compare the medical team’s experience, participation in clinical trials, and how often they treat similar cancers. The Airomedical portal cuts through the noise and shows which centers really work with alpha‑therapy.
Leading German Centers Frequently Consulted for Actinium‑225 Therapy
Several hospitals are consistently considered by patients seeking Actinium‑225 therapy. That is largely because their nuclear medicine teams have long‑standing experience with radioligand treatments and were early adopters of alpha‑emitters. According to Airomedical’s clinical profiles, among the leading German clinics for radioligand therapy:
- University Hospital Heidelberg.
- University Hospital Rechts der Isar, Munich.
- University Hospital Essen.
- University Hospital Saarland, Homburg.
- Helios Hospital Berlin‑Buch.
- University Hospital LMU Munich.
- DKD Helios Clinic Wiesbaden.
These centers have contributed to much of the clinical work on radioligand therapy in Germany and continue to treat some of the highest patient volumes in Europe. Many patients begin their decision‑making process by reviewing the profiles of specialists from these hospitals on Airomedical before requesting a remote case evaluation.
Best Radioligand Therapy Doctors
For Actinium‑225 therapy, the doctor’s experience matters just as much as the hospital. Only a few departments actually use alpha‑emitters, and the results depend on how well the team reads the scans, adjusts the dose, and follows the patient over time. That’s why patients start by looking at specialists who’ve been doing radioligand therapy for years.
According to Airomedical’s clinical profiles, patients most often look at experts from major German centers with long‑standing experience in PSMA‑targeted and alpha‑emitter treatments. These departments were among the early adopters of Actinium‑225 and continue to treat some of the highest patient volumes in Europe. Most patients compare two or three specialists, submit their medical records for a remote review, and then decide where to proceed.
Typical Patient Pathway: What to Expect
Delays usually happen right at the start — patients need to gather scans and reports, and German clinics are strict about PSMA PET/CT quality. Once the files are in, the remote review is fast, and the first opinion comes within a few days.
Travel plans are not the same for everyone. Some patients may come next week, others may wait a bit longer. The stay is usually brief: blood tests, maybe a scan, an injection, and one or two days of checks.
The slow part is after going home. Actinium‑225 does not show its effect immediately, and the time before the first control scan can feel long. Doctors in Germany keep in touch, review new lab results, and answer questions. When the next PSMA PET/CT is performed, it will become clearer what to do next.
Risks and Limitations of Actinium‑225 Therapy
Actinium‑225 therapy is generally well tolerated, but there are limitations patients should understand. The most common side effect is dry mouth, since salivary glands also take up PSMA and receive part of the dose. Changes in blood counts can occur as well, especially in those who have had extensive prior treatment.
The therapy depends on how strongly the tumor expresses PSMA. When uptake is low, the response becomes harder to predict, and the team sometimes suggests another option. There is also an issue with availability. Actinium‑225 is produced in very small amounts, so clinics plan their schedules around whatever supply they receive.
What Influences the Cost of Actinium‑225 Treatment
The treatment cost depends on several factors. The biggest factor is how many cycles a patient needs, usually two or three. Extra tests can add to the price, especially if the clinic has to repeat an imaging or update bloodwork.
Costs also change from center to center. Some treat everything as outpatient care, and others keep patients for short monitoring. Follow‑up visits may be included or billed separately. Because of all these differences, clinics usually give a personal estimate after reviewing the medical files.
Best Way for International Patients to Arrange Treatment in Germany
For patients traveling from abroad, the hardest part of accessing Actinium‑225 therapy is usually the coordination, not the treatment itself. German hospitals rely on complete medical records and high‑quality imaging, which can be difficult to organize across countries and time zones. Many patients use the Airomedical platform as a practical bridge — not instead of the hospital, but to help structure the process.
The Airomedical matches patients with hospitals that treat similar cases. They check the doctors’ backgrounds and confirm the clinic’s experience with radioligand therapy. For patients who want a more structured plan, it is also possible to book treatment programs with clear steps and timing.
FAQ
How many cycles do patients usually receive?
Most patients end up having two or three cycles, with a few weeks between them. The choice depends on the follow‑up scan and lab results.
Do I need a new PSMA PET/CT scan before traveling?
Usually yes. German teams rely on high‑quality imaging, and older scans may need to be repeated. The clinic confirms this during the remote review.
How should international patients choose a hospital?
For Actinium‑225, it makes more sense to look at the nuclear medicine department rather than general hospital ratings. Airomedical helps patients see which centers actually treat international cases and have experience with radioligand therapy.
How do foreigners book treatment programs?
After the doctor confirms eligibility for Actinium‑225 therapy, some patients can book the treatment program directly through the clinic. Others prefer Airomedical to coordinate all the processes.
How can I compare doctors and clinics if I don’t know the system?
Focus on the specialist’s experience with radioligand therapy rather than the hospital’s brand. Airomedical platform verifies doctor profiles and ensures the appropriate team reviews the case.
References
- Sathekge M., Lawal I., Bal C., et al. Actinium‑225‑PSMA radioligand therapy of metastatic castration‑resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncology. 2024.
- Mudr. Popel A., Dr. Ahmed F. Actinium-225 PSMA Therapy for Prostate Cancer. Airomedical. 2026.
- Ninatti G., Scilipoti P., Pini C., et al. Time for action: actinium‑225 PSMA‑targeted alpha therapy for metastatic prostate cancer – a systematic review and meta‑analysis. Theranostics. 2025.
- Mudr. Popel A. & Dr. Volvak M. Top Nuclear Medicine Theranostics Teams in Germany. Airomedical. 2026.
- Roustaei H., D’Alessandria C., Decristoforo C. Navigating the safety profile of Actinium‑225 targeted alpha therapy: a comprehensive review. Clinical and Translational Imaging. 2025.